Stock listing
Hamburg:HQ1 Oruka Therapeutics, Inc. Aktie
German listing (Hamburg) of Oruka Therapeutics, Inc. · home listing NASDAQ:ORKA
Follow Oruka Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:ORKA
$95.81 USD +0.07 (+0.1%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ORKA
- Day range
- $93.30 – $97.24 USDNov 20, 2026
- Volume
- 1.98M sharesNov 20, 2026
- Market cap
- $6.50B USDAt the close on Nov 20, 2026 · price × 67.82M shares outstanding
- 52-week range
- $25.23 – $115.52 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $88.52M USDMedian day 822,160 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ORKA · Home | $95.81 USD | +0.07 (+0.1%) | 1,977,006 | $95.86 | $97.24 | $93.30 | $95.74 | Close on Nov 20, 2026 |
| Frankfurt:HQ1 | €88.00 EUR | +1.00 (+1.1%) | — | €88.00 | €88.00 | €88.00 | €87.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ORKA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $95.81 | +0.07 | +0.1% | $95.86 | $97.24 | $93.30 | 1,977,006 | |
| $95.74 | -0.58 | -0.6% | $96.31 | $99.11 | $95.07 | 521,772 | |
| $96.32 | -2.92 | -2.9% | $98.51 | $100.77 | $95.05 | 780,179 | |
| $99.24 | -6.11 | -5.8% | $104.10 | $107.50 | $98.89 | 989,987 | |
| $105.35 | +0.36 | +0.3% | $104.89 | $106.87 | $101.56 | 679,677 | |
| $104.99 | -2.18 | -2.0% | $105.10 | $107.00 | $101.50 | 1,141,814 | |
| $107.17 | -2.33 | -2.1% | $112.28 | $112.42 | $106.26 | 844,076 | |
| $109.50 | +4.94 | +4.7% | $103.84 | $113.24 | $102.78 | 2,611,570 | |
| $104.56 | +1.70 | +1.7% | $104.56 | $108.08 | $103.46 | 1,598,894 | |
| $102.86 | +6.84 | +7.1% | $97.99 | $103.75 | $96.05 | 1,070,244 | |
| $96.02 | -5.39 | -5.3% | $100.02 | $100.73 | $94.05 | 846,558 | |
| $101.41 | +1.86 | +1.9% | $102.37 | $102.59 | $96.34 | 790,242 | |
| $99.55 | +4.12 | +4.3% | $97.48 | $101.41 | $95.29 | 822,160 | |
| $95.43 | -1.44 | -1.5% | $98.85 | $99.83 | $94.29 | 654,335 | |
| $96.87 | +0.22 | +0.2% | $94.87 | $97.60 | $94.75 | 633,810 | |
| $96.65 | +0.68 | +0.7% | $97.04 | $98.88 | $95.26 | 657,177 | |
| $95.97 | +0.16 | +0.2% | $95.26 | $98.45 | $94.17 | 798,075 | |
| $95.81 | +5.48 | +6.1% | $89.02 | $96.59 | $89.02 | 1,205,199 | |
| $90.33 | +10.18 | +12.7% | $81.98 | $93.42 | $81.98 | 1,942,729 | |
| $80.15 | -1.00 | -1.2% | $81.15 | $81.15 | $79.07 | 514,000 | |
| $81.15 | +1.23 | +1.5% | $79.06 | $82.15 | $78.36 | 589,900 | |
| $79.92 | +0.83 | +1.0% | $79.97 | $81.75 | $79.48 | 953,400 | |
| $79.09 | +4.61 | +6.2% | $74.42 | $79.90 | $74.42 | 787,700 | |
| $74.48 | +2.55 | +3.5% | $72.40 | $76.35 | $72.30 | 812,700 | |
| $71.93 | -1.94 | -2.6% | $73.75 | $74.26 | $70.50 | 1,388,200 | |
| $73.87 | -2.81 | -3.7% | $75.53 | $77.89 | $73.15 | 1,222,100 | |
| $76.68 | -1.51 | -1.9% | $77.37 | $78.57 | $75.41 | 685,300 | |
| $78.19 | -2.16 | -2.7% | $79.47 | $80.19 | $78.18 | 503,100 | |
| $80.35 | -1.76 | -2.1% | $81.81 | $82.95 | $79.43 | 547,900 | |
| $82.11 | +4.83 | +6.2% | $77.24 | $82.24 | $77.00 | 1,206,700 | |
| $77.28 | -2.22 | -2.8% | $78.47 | $80.19 | $75.83 | 1,225,000 | |
| $79.50 | -0.68 | -0.8% | $79.01 | $81.40 | $78.52 | 809,900 | |
| $80.18 | -4.20 | -5.0% | $84.94 | $84.94 | $77.78 | 1,122,000 | |
| $84.38 | -0.14 | -0.2% | $84.52 | $85.23 | $81.83 | 629,600 | |
| $84.52 | +1.10 | +1.3% | $84.81 | $86.00 | $83.33 | 581,500 | |
| $83.42 | +0.13 | +0.2% | $82.85 | $85.00 | $82.50 | 921,000 | |
| $83.29 | +1.14 | +1.4% | $83.33 | $86.51 | $82.27 | 1,535,600 | |
| $82.15 | -2.04 | -2.4% | $83.32 | $84.67 | $81.11 | 1,363,300 | |
| $84.19 | -0.27 | -0.3% | $83.94 | $85.95 | $83.22 | 923,300 | |
| $84.46 | -1.03 | -1.2% | $86.49 | $86.49 | $84.00 | 499,700 | |
| $85.49 | -4.44 | -4.9% | $88.83 | $89.18 | $82.70 | 1,294,400 | |
| $89.93 | -4.62 | -4.9% | $94.08 | $95.81 | $85.00 | 1,993,000 | |
| $94.55 | +1.17 | +1.3% | $93.38 | $96.78 | $91.53 | 1,054,900 | |
| $93.38 | -1.58 | -1.7% | $95.75 | $96.00 | $91.75 | 1,185,400 | |
| $94.96 | -2.77 | -2.8% | $98.18 | $98.29 | $94.52 | 1,943,000 | |
| $97.73 | +4.18 | +4.5% | $94.93 | $98.02 | $94.05 | 1,046,900 | |
| $93.55 | +1.35 | +1.5% | $92.70 | $95.46 | $92.19 | 927,000 | |
| $92.20 | -3.73 | -3.9% | $95.14 | $95.81 | $90.41 | 784,600 | |
| $95.93 | +3.55 | +3.8% | $92.56 | $97.48 | $92.55 | 773,800 | |
| $92.38 | +0.73 | +0.8% | $93.40 | $94.29 | $90.48 | 585,300 | |
| $91.65 | +0.15 | +0.2% | $90.21 | $92.29 | $88.07 | 554,600 | |
| $91.50 | -2.81 | -3.0% | $93.59 | $94.85 | $91.23 | 525,000 | |
| $94.31 | +1.80 | +1.9% | $90.06 | $96.44 | $87.68 | 868,300 | |
| $92.51 | +1.52 | +1.7% | $90.06 | $94.00 | $89.38 | 600,500 | |
| $90.99 | -0.64 | -0.7% | $91.72 | $93.69 | $90.12 | 732,600 | |
| $91.63 | -0.48 | -0.5% | $93.05 | $96.20 | $89.88 | 671,700 | |
| $92.11 | -0.51 | -0.6% | $90.78 | $93.20 | $90.27 | 596,200 | |
| $92.62 | +1.47 | +1.6% | $91.00 | $93.88 | $86.00 | 1,292,900 | |
| $91.15 | -5.39 | -5.6% | $95.08 | $95.45 | $91.01 | 589,400 | |
| $96.54 | -2.90 | -2.9% | $98.93 | $99.62 | $96.16 | 614,600 | |
| $99.44 | -2.38 | -2.3% | $101.30 | $102.48 | $98.24 | 526,700 | |
| $101.82 | -0.60 | -0.6% | $104.74 | $106.91 | $100.29 | 1,308,022 | |
| $102.42 | -5.54 | -5.1% | $106.75 | $107.23 | $100.64 | 992,276 | |
| $107.96 | +3.10 | +3.0% | $105.48 | $109.52 | $103.86 | 935,800 | |
| $104.86 | -4.83 | -4.4% | $107.72 | $109.01 | $103.14 | 778,900 |
Splits
6 splits since 2004 · NASDAQ:ORKA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation | |
| 1-for-18 | Consolidation | |
| 1-for-7 | Consolidation | |
| 1-for-6 | Consolidation | |
| 1-for-20 | Consolidation | |
| 1-for-3 | Consolidation |
- Ticker
- Hamburg:HQ1
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Hamburg
- Currency
- EUR
What changed lately
Latest news release · Nov 9, 2026
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 28 slides
Latest news
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 9, 2026
Closed $109.50 (+4.7%) on Nov 10, 2026
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
Nov 3, 2026
Closed $99.55 (+4.3%) on Nov 3, 2026
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
Oct 26, 2026
Closed $90.33 (+12.7%) on Oct 26, 2026
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
Oct 25, 2026
Closed $90.33 (+12.7%) on Oct 26, 2026
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
Sep 23, 2026
Closed $89.93 (-4.9%) on Sep 23, 2026
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
Sep 9, 2026
Closed $91.65 (+0.2%) on Sep 10, 2026
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
Aug 24, 2026
Closed $101.82 (-0.6%) on Aug 25, 2026
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 10, 2026
Closed $105.14 (+6.4%) on Aug 10, 2026
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Closed $57.98 (0.0%) on May 28, 2026
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Closed $63.90 (+1.1%) on May 14, 2026
Oruka Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 87 in all · newest Nov 9, 2026 · oldest 2019
- Decks
- 23 decks · latest November 2026
Where Oruka Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ORKA · Home listing | NASDAQ | United States | USD |
| gettex:HQ1 | gettex | Germany | EUR |
| BOATS:ORKA | BOATS | United States | USD |
| LS Exchange:A3DPH3 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3DPH3 | Lang & Schwarz | Germany | EUR |
| Tradegate:HQ1 | Tradegate | Germany | EUR |
| Dusseldorf:HQ1 | Dusseldorf | Germany | EUR |
| Munich:HQ1 | Munich | Germany | EUR |
| Frankfurt:HQ1 | Frankfurt | Germany | EUR |
| Stuttgart:HQ1 | Stuttgart | Germany | EUR |
| Hamburg:HQ1 · This page | Hamburg | Germany | EUR |
| Hanover:HQ1 | Hanover | Germany | EUR |
| Xetra:HQ1 | Xetra | Germany | EUR |
Cash and shares
Jul 31, 2026 · Oruka Therapeutics — Investor Presentation (October 2026)
- Shares outstanding
- 66.2 million
Valuation
Price/book 5.4× against a median of 24.9×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $5.58B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.30
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Oruka Therapeutics, Inc. · NASDAQ:ORKA | US$6.50B | US$5.58B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.30 |
| CG Oncology, Inc. · NASDAQ:CGON | US$7.10B | US$6.12B | n/a | 992× | n/a | 7.2× | n/a | 0.0× | 0.83 |
| Cytokinetics, Incorporated · NASDAQ:CYTK | US$7.07B | US$6.36B | n/a | 56.2× | n/a | n/a | −686.6% | n/a | 0.93 |
| Axsome Therapeutics, Inc. · NASDAQ:AXSM | US$6.80B | US$6.68B | n/a | 7.7× | n/a | 64.5× | −18.2% | 1.8× | 0.69 |
| Akeso, Inc. · HKEX:9926 | US$6.66B | US$6.04B | n/a | 13.5× | n/a | 5.2× | −36.4% | 0.6× | n/a |
| Immunovant, Inc. · NASDAQ:IMVT | US$6.57B | US$5.85B | n/a | 825× | n/a | 10.0× | n/a | 0.0× | 1.46 |
| ImmunityBio, Inc. · NASDAQ:IBRX | US$6.40B | US$6.10B | n/a | 33.4× | n/a | n/a | −607.8% | n/a | 1.50 |
| Kodiak Sciences Inc · NASDAQ:KOD | US$6.35B | US$6.31B | n/a | n/a | n/a | 505× | n/a | 3.7× | 1.58 |
| Abivax SA · EURONEXT:ABVX | US$6.05B | US$5.60B | n/a | n/a | n/a | 15.1× | n/a | 0.0× | n/a |
| Scholar Rock Holding Corporation · NASDAQ:SRRK | US$5.87B | US$5.65B | n/a | 9,921× | n/a | 34.8× | n/a | 1.2× | 0.91 |
| Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWR | US$5.85B | US$4.66B | n/a | 10.3× | n/a | 116× | −160.6% | 0.0× | 1.34 |
| Median of the others | US$6.49B | US$6.07B | 44.8× | 24.9× | −160.6% | 0.3× | 1.14 |
Forecasts
11 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 156.17 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.52 · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Todd Edwards | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Carl Dambkowski | Director |
| Chris Martin | Director |
| Kristine Ball | Director |
| Peter Harwin | Director |
| Samarth Kulkarni | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | +4.7% |
| Q2 2026 | Aug 10, 2026 · Before open | +6.4% |
| Q1 2026 | May 13, 2026 · After close | +1.1% |
| Q4 2025 | Mar 13, 2026 | +30.5% |
| Q3 2025 | Nov 12, 2025 · After close | −6.8% |
| Q2 2025 | Aug 11, 2025 · After close | +6.9% |
| Q1 2025 | May 14, 2025 · After close | −2.6% |
| Q4 2024 | Mar 6, 2025 | +0.8% |
| Q3 2024 | Nov 13, 2024 · After close | −6.4% |
| Q2 2024 | Aug 27, 2024 · Before open | +1.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 25, 2024 | −1.4% |
| Q4 2023 | Feb 1, 2024 | +1.9% |
| Q3 2023 | Nov 7, 2023 | 0.0% |
| Q2 2023 | Jul 21, 2023 | 0.0% |
| Q1 2023 | Apr 24, 2023 | +1.0% |
| Q4 2022 | Feb 24, 2023 | +3.3% |
| Q3 2022 | Oct 28, 2022 | +2.9% |
| Q2 2022 | Aug 2, 2022 | −2.9% |
| Q1 2022 | May 2, 2022 | +1.7% |
| Q4 2021 | Mar 14, 2022 | +2.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 28 slides | November 2026 |
| Corporate Update (October 2026) | Corporate update | 21 slides | Oct 26, 2026 |
| Investor Presentation (October 2026) | Investor deck | 28 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 30 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 30 slides | August 2026 |
| Investor Presentation (June 2026) | Investor deck | 29 slides | June 2026 |
| Investor Presentation (May 2026) | Investor deck | 29 slides | May 2026 |
| Technical Presentation (April 2026) | Technical | 22 slides | Apr 27, 2026 |
| Investor Presentation (March 2026) | Investor deck | 36 slides | March 2026 |
| Investor Presentation (January 2026) | Investor deck | 38 slides | January 2026 |
All 23 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Made bigger: about US$700.4M · US$72.5 a share · Leerink Partners +5 Dealers: Leerink Partners (co-lead), TD Cowen (co-lead), Goldman Sachs & Co. LLC (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), LifeSci Capital | Apr 28, 2026 |
| Private placement of common stock and pre-funded warrants Closed: US$180M raised · US$15 a share · Jefferies +3 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead) Buyers: Viking Global Investors (led the PIPE financing); Affinity Healthcare Fund; Blackstone Multi-Asset Investing; Commodore Capital; Cormorant Asset Management; Deep Track Capital; Fairmount; Great Point Partners, LLC; Palo Alto Investors, LP; Perceptive Advisors; Surveyor Capital; Venrock Healthcare Capital Partners Use of proceeds: Extend cash runway over one year past three Phase 2 readouts (ORKA-001 Phase 2a and 2b, ORKA-002 Phase 2) | Nov 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 83.0K | 27.0K | 111.0K | 114.0K | 91.0K | 93.0K | 89.0K | 22.0K | 27.0K | 24.0K |
| Gross profit | -83.0K | -27.0K | -111.0K | -114.0K | -91.0K | -93.0K | -89.0K | -22.0K | -27.0K | -24.0K |
| Research and development | 100.6M | 75.1M | 1.01M | 4.75M | 13.8M | 4.99M | 1.83M | 4.24M | 14.1M | 12.3M |
| Selling, general and administrative | 21.4M | |||||||||
| Operating income | -122.1M | -88.1M | -7.30M | -10.6M | -19.3M | -9.77M | -5.81M | -8.12M | -18.7M | -16.6M |
| Depreciation and amortization | 83.0K | 27.0K | 15.0K | 20.0K | 16.0K | 8.00K | 18.0K | 22.0K | 27.0K | 24.0K |
| EBITDA | -122.0M | -88.1M | -7.28M | -10.6M | -19.3M | -9.76M | -5.80M | -8.10M | -18.7M | -16.6M |
| Interest expense | 0 | 1.47M | 9.00K | 7.00K | 8.00K | 6.00K | ||||
| Income before tax | -105.4M | -83.7M | -5.34M | -9.93M | -19.3M | -9.75M | -5.65M | -7.96M | -18.6M | -16.4M |
| Income tax | 0 | 0 | 0 | -9.00K | -167.0K | -31.0K | -61.0K | 0 | ||
| Net income | -105.4M | -83.7M | -5.34M | -9.93M | -19.3M | -9.74M | -5.48M | -7.93M | -18.5M | -16.4M |
| Earnings per share, basic | -2.16 | -4.99 | -0.37 | -0.69 | -1.39 | -2.07 | -4.15 | -10.31 | -1.77 | -1.81 |
| Earnings per share, diluted | -0.37 | -0.69 | -1.39 | -2.07 | -4.15 | -10.31 | -1.77 | -1.81 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 46.9M | 61.6M | 37.4M | 42.4M | 53.4M | 49.1M | 8.36M | 6.61M | 8.70M | 7.40M |
| Short-term investments | 290.1M | 314.1M | 3.05M | 13.8M | ||||||
| Current assets | 343.9M | 376.9M | 37.6M | 42.7M | 54.4M | 50.0M | 8.48M | 6.78M | 12.3M | 21.4M |
| Property, plant and equipment | 288.0K | 10.0K | 25.0K | 48.0K | 21.0K | 10.0K | 24.0K | 42.0K | 66.0K | |
| Total assets | 488.6M | 396.0M | 37.9M | 43.1M | 54.9M | 50.4M | 8.54M | 6.83M | 12.4M | 24.6M |
| Accounts payable | 4.16M | 3.46M | 362.0K | 334.0K | 1.12M | 1.77M | 418.0K | 230.0K | 622.0K | 1.21M |
| Current liabilities | 15.4M | 13.0M | 637.0K | 1.13M | 3.50M | 3.50M | 926.0K | 793.0K | 2.07M | 2.40M |
| Total debt | 1.93M | 968.0K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total liabilities | 16.7M | 13.8M | 841.0K | 1.41M | 3.88M | 3.91M | 926.0K | 793.0K | 2.09M | 2.44M |
| Shareholders' equity | 471.9M | 382.2M | 37.0M | 41.7M | 51.0M | 46.5M | 7.61M | 6.03M | 10.3M | 22.2M |
| Shares outstanding | 48.7M | 16.8M | 14.5M | 14.4M | 14.4M | 9.55M | 1.59M | 773.6K | 11.8M | 9.08M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -88.2M | -57.8M | -5.01M | -10.9M | -18.8M | -7.72M | -4.80M | -8.24M | -17.5M | -15.0M |
| Capital spending | -209.0K | -189.0K | 0 | -2.00K | -43.0K | -19.0K | -4.00K | -4.00K | -3.00K | -12.0K |
| Free cash flow | -88.4M | -58.0M | -5.01M | -10.9M | -18.8M | -7.74M | -4.80M | -8.25M | -17.5M | -15.0M |
| Cash from investing | -96.7M | -330.1M | 0 | -2.00K | -43.0K | -19.0K | -4.00K | 3.05M | 12.9M | -16.4M |
| Cash from financing | 170.3M | 449.5M | 0 | 0 | 23.1M | 48.5M | 6.56M | 3.10M | 5.85M | |
| Change in cash | -14.6M | 24.1M | -5.01M | -10.9M | 4.29M | 40.7M | 1.75M | -2.09M | 1.30M | -31.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 26, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Aug 28, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 28, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 24, 2026 | Management or board change | SEC |
| S-3 · Registration statement | Aug 21, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 1, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 4, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 30, 2026 | Results | SEC |
| 424B5 · Prospectus | Apr 29, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Apr 27, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Apr 27, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 27, 2026 | Current report | SEC |
| 424B7 · Prospectus | Apr 21, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 17, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 13, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 8, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 7, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 2, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 424B3 · Prospectus | Nov 5, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Nov 5, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| S-3/A · Registration statement, amended | Oct 14, 2025 | Offer document | SEC |
| S-3/A · Registration statement, amended | Oct 14, 2025 | Offer document | SEC |
| S-3 · Registration statement | Oct 3, 2025 | Offer document | SEC |
| S-3 · Registration statement | Oct 3, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 24, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Sep 22, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 22, 2025 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 19, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Aug 11, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | May 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 13, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 18, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 18, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 12, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 10, 2025 | Big-stake notice | SEC |
| POS AM · Amendment to an effective registration | Mar 6, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 6, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 27, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 5, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 19, 2024 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Nov 27, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 22, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 22, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 21, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 18, 2024 | Meeting outcome | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 14, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 14, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| S-1 · Registration statement | Nov 14, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 22, 2024 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Oct 18, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 7, 2024 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Oct 7, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 4, 2024 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 13, 2024 | Material contract | SEC |
| SC 13D · Big-stake notice | Sep 6, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Sep 6, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 6, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 6, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 6, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 6, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 6, 2024 | Insider trade | SEC |
This page holds 200 of 1,002 filings. Open Filings
Cap table
Built by 6ix from Oruka Therapeutics, Inc.’s releases · as of Oct 31, 2026
- Common shares
- 67,822,359
- Fully diluted
- 67,822,359
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 67,822,359 | Oct 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 31, 2026 | 67,822,359 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jean-François Formela Other companies: Korro Bio, Inc. (Co-Founder & Director · Since at least Nov 3, 2023); ImageneBio, Inc. (Director · Mar 25, 2021 – Jun 7, 2024 · Past); Translate Bio Inc (Director · Jun 27, 2018 – Sep 14, 2021 · Past); Spero Therapeutics, Inc. (Director · Nov 1, 2017 – Aug 17, 2021 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – Jun 14, 2022 · Past); Egalet Corporation (Director · Feb 5, 2014 – Feb 11, 2014 · Past); Horizon Pharma PLC (Director · Jul 28, 2011 – Mar 2, 2012 · Past) | Director · Feb 10, 2012 – Oct 22, 2012 · Past |
| Samarth Kulkarni Other companies: Centessa Pharmaceuticals PLC (Director · Since at least May 27, 2021); Black Diamond Therapeutics, Inc. (CEO, CRISPR Therapeutics AG · Since at least Jan 29, 2020); CRISPR Therapeutics AG (Chief Executive Officer and Chairman of the Board · Since at least Oct 18, 2016); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past) | Director · Since at least Aug 29, 2024 |
| James Flynn Other companies: Lite Strategy, Inc. (Director · Since at least Oct 31, 2023); Synlogic Inc (Director · Mar 19, 2024 – Apr 26, 2025 · Past); RiceBran Technologies (Director · Jan 3, 2024 – Jan 3, 2024 · Past) | Director · Jan 30, 2024 – Jan 30, 2024 · Past |
| Carl Dambkowski Other companies: Apogee Therapeutics, Inc. (Chief Medical Officer · Since at least Apr 2, 2025) | Director · Since at least Jun 2, 2025 |
| Robert E Conway Other companies: Alpine Immune Sciences Inc (Director · Jun 16, 2015 – May 20, 2024 · Past) | Director · Sep 3, 2013 – Jan 30, 2024 · Past |
| Anders D Hove | Director · Mar 1, 2018 – Jan 30, 2024 · Past |
| Arjun Agarwal | Senior Vice President, Finance · Since at least Aug 29, 2024 |
| Chris Martin | Director · Since at least Dec 11, 2025 |
| Christopher David Ozeroff | S.V.P., General Counsel · May 26, 2010 – Dec 14, 2021 · Past |
| C Jeffrey Dekker | Chief Financial Officer · May 10, 2021 – Dec 8, 2022 · Past |
All 18 people
| Person | Seat |
|---|---|
| Joana Goncalves | Chief Medical Officer · Since at least Apr 15, 2026 |
| Kristine Ball | Director · Since at least Nov 5, 2026 |
| Larry Todd Edwards | Chief Commercial Officer · Since at least Aug 24, 2026 |
| Michael R Bristow | Pres. & Chief Executive Offic, Director · Dec 21, 2020 – Dec 14, 2021 · Past |
| Paul T Quinlan | General Counsel · Since at least Jun 15, 2026 |
| Peter Harwin | Director · Since at least Nov 5, 2026 |
| Thomas A Keuer | Chief Operating Officer · Dec 8, 2022 – Dec 8, 2022 · Past |
| Todd Edwards | Chief Commercial Officer · Since at least Aug 24, 2026 |
Log in to ask 6ix AI your own questions about Oruka Therapeutics, Inc.